Initial Management of Newly Diagnosed Type 2 Diabetes with Elevated A1C

Immediate Treatment and Rationale

The American Diabetes Association recommends starting metformin 500 mg once or twice daily with meals and simultaneously initiating basal insulin at 10 units daily or 0.1-0.2 units/kg/day for patients with A1C ≥9% 1, 2
Dual therapy should be initiated immediately in patients with A1C ≥9% rather than starting with metformin monotherapy alone, as metformin monotherapy will typically reduce A1C by only 1-2%, leaving the patient well above goal 1, 2, 3

Start metformin 500 mg once daily with dinner or 500 mg twice daily with meals to minimize gastrointestinal side effects, and increase by 500 mg weekly as tolerated until reaching 2000 mg daily (1000 mg twice daily) 1, 2, 3
The American Diabetes Association suggests that basal insulin can be started at 10 units daily or 0.1-0.2 units/kg/day, and the dose can be increased by 2 units every 3 days until fasting plasma glucose reaches 80-130 mg/dL 1, 3

Check fasting blood glucose daily during insulin titration to guide dose adjustments, and recheck A1C in 3 months to assess response to therapy 1, 4, 3, 5
Monitor for hypoglycemia symptoms and provide patient education on recognition and treatment with 15-20 grams of fast-acting carbohydrate 1, 4, 5

If A1C remains >7% after 3 months on metformin plus basal insulin, consider adding prandial insulin or a GLP-1 receptor agonist, especially if the patient has or is at high risk for cardiovascular disease 1, 2, 3
Prioritize adding an SGLT2 inhibitor or GLP-1 receptor agonist with proven cardiovascular benefit for patients with established atherosclerotic cardiovascular disease 1, 2

Teach proper insulin injection technique, systematic rotation of injection sites, hypoglycemia recognition and treatment, and emphasize the importance of medication adherence and lifestyle modifications including diet and physical activity 1, 4, 3

The American Diabetes Association recommends early insulin introduction at A1C ≥10% due to evidence of ongoing catabolism and very high glucose levels, which applies to patients with A1C levels like 10.4% 6

Basal insulin analogues are preferred over NPH insulin due to reduced risk of hypoglycemia, particularly nocturnal hypoglycemia, in patients starting insulin therapy 6
The insulin can be administered at any time of day with newer analogues, though bedtime is traditional, allowing for flexible dosing 6

If A1C remains >7% after 3 months on optimized metformin plus basal insulin, adding a GLP-1 receptor agonist is preferred due to its efficacy and lower risk of hypoglycemia and weight gain 6
For patients with established atherosclerotic cardiovascular disease or heart failure, adding an SGLT2 inhibitor or GLP-1 receptor agonist with proven cardiovascular benefit is recommended, as per the American College of Cardiology guidelines 7

Referring patients to diabetes self-management education and support (DSMES) services is crucial for comprehensive care, as emphasized by the American Diabetes Association 6